Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

INTRODUCTION: Cardiovascular disease (CVD) remains the leading global cause of mortality. To advance prevention, the American Heart Association introduced Life's Simple 7 (LS7) in 2010 and updated it in 2022 to Life's Essential 8 (LE8). This paper reviews the development, scientific foundation, and predictive validity of LE8 across major U.S. and international cohorts, including its applications beyond cardiovascular health. AREAS COVERED: A comprehensive search on PubMed, EMBASE, and Scopus was conducted through December 2025 to identify studies evaluating LS7 and LE8 in U.S. and international populations. Evidence from prospective cohorts, registries, and validation studies was synthesized to assess predictive value and clinical applications. LE8 incorporates diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose, and blood pressure, each scored on a 0-100 scale. Higher LE8 scores consistently predict lower risks of CVD, stroke, heart failure, cognitive decline, and all-cause mortality. Data from major cohorts (NHANES, ARIC, CARDIA, REGARDS) confirm its prognostic validity, while international studies demonstrate external reproducibility. EXPERT OPINION: LE8 provides a practical framework for cardiovascular health assessment and risk communication, with potential benefits for prevention and healthcare cost reduction. However, limitations in clinical implementation, incomplete consideration of psychosocial and environmental factors, and reliance on self-reported measures remain important challenges.